GlassScriptPhysician profile
Alvin Vong
NPI 1164985503
$7,067.07
in general payments reported to CMS, 2019-2025
20 companies · $1,824 in 2025
The $1,824 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.52 · 2022: $1,838 · 2023: $1,913 · 2024: $1,425 · 2025: $1,824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,161.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,279.54 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,137.14 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $891.73 | 2022-2025 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $808.75 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $713.39 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Gilead Sciences, INC. | $565.69 | 2022-2023 | Epclusa, Vemlidy |
| Bayer Healthcare Pharmaceuticals INC. | $377.15 | 2022-2025 | |
| Corcept Therapeutics | $346.19 | 2024-2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $271.27 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.79 | 2024 | Jardiance |
| Dexcom, INC. | $132.70 | 2023 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $97.74 | 2022 | |
| Sumitomo Pharma America, INC. | $84.93 | 2025 | Gemtesa |
| Exact Sciences Corporation | $80.81 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $40.61 | 2022-2024 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $39.06 | 2023-2025 | Aptima, Thinprep 2000 Processor, Third Wave |
| Biohaven Pharmaceutical Holding Company LTD. | $20.55 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $19.33 | 2025 | Zoryve |
| Abbvie INC. | $14.19 | 2023 | Ubrelvy |
| Mayne Pharma Commercial LLC | $5.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvin Vong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.